Secukinumab provides sustained improvement in signs and symptoms and low radiographic progression in patients with psoriatic arthritis: 2-year (end-of-study) results from the FUTURE 5 study

Secukinumab provides sustained improvement in signs and symptoms and low radiographic progression in patients with psoriatic arthritis: 2-year (end-of-study) results from the FUTURE 5 study

Objective Secukinumab provided sustained efficacy, low radiographic progression and consistent safety over 52 weeks in patients with psoriatic arthritis (PsA) in the FUTURE 5 study. Here, we report 2-year (end-of-study) results from this study.Methods Adults with active PsA were randomised 2:2:2:3 t...

Full description

Bibliographic Details
Main Authors: Robert Landewé, Désirée van der Heijde, Philip J Mease, Hasan Tahir, Shephard Mpofu, Luminita Pricop, Proton Rahman, Atul Singhal, Sandra Navarra, Aimee Readie, Elke Boettcher, Eumorphia Maria Delicha
Format: Article
Language:English
Published: BMJ Publishing Group 2021-08-01
Series:RMD Open
Online Access:https://rmdopen.bmj.com/content/7/2/e001600.full

Internet

https://rmdopen.bmj.com/content/7/2/e001600.full

Similar Items